Baseline ALBI Grade as an Independent Prognostic Factor of Survival in High-Risk Real-World HCC Under Atezolizumab-Bevacizumab
{{output}}
Background/aim: Atezolizumab plus bevacizumab is the current first-line standard for unresectable hepatocellular carcinoma (HCC). However, real-world populations often differ substantially from clinical trials particularly in ter... ...
